Should Aflac Be Your Next Buy?
A week ago, I took up the challenge of corralling my easily distracted brain long enough to dig into five stocks that look very promising. Thus far, I've taken a close look at four of the five stocks that I highlighted:
Today, I'll round off the five with a dive into the ducky world of Aflac (NYS: AFL) .
Aflac: What it is, jive turkey
For those familiar with the insurance industry, Aflac's business is immediately familiar. Like any insurer, Aflac's business is taking on a certain financial risk for its customers in exchange for an upfront payment. Like other insurers, Aflac makes its profit in two primary ways. First, when it does a good job pricing the risk that it's assuming, it gets to pocket some of the premiums it collects. Second, since it collects payments up front and pays out for claims later, the company can invest the premiums it collects and keep the investment returns.
But it's the specific type of product that Aflac offers that sets the company apart. In Japan, the company's business is largely weighted toward supplemental medical coverage, including cancer-specific insurance, while its U.S. business offers supplemental coverage that can help defray non-medical costs as well.
The market for supplemental insurance is not nearly as big as the traditional health insurance coverage offered by companies like UnitedHealth Group (NYS: UNH) and WellPoint (NYS: WLP) . However, when it comes to large, standardized insurance markets like health, auto, or life, there is far more competition and fighting for customers can often come down simply to pricing. There are still great businesses in those industries, but selling a commoditized product can be brutal.
So while Aflac's niche sacrifices overall market size, its focus has allowed it to become the 500-pound gorilla in its specialties in both Japan and the U.S.
Forget the U.S.
We certainly don't want to completely ignore the U.S. when it comes to Aflac's business -- particularly its future. However, if you're looking for a starting point for understanding the company, the U.S. isn't it. Why do I say this? For the first six months of the year, the pre-tax operating income of the company's U.S. division was $499 million versus $1.9 billion for its operations in Japan. Not only that, but with a 21.7% operating margin, Aflac's Japanese arm is also more profitable.
This heavy exposure to Japan comes with a number of positives. Japan is facing the problem of a government-run health-care system trying to deal with an aging population. That has the potential to put a greater burden on individuals, which would make Aflac's policies even more attractive. Culturally, Japan also tends to be more financially conservative, and this is good for both Aflac's health-related policies, as well as its flexible life-insurance policies that provide benefits for things like a child's education.
The exposure to Japan is also advantageous because it's ... well, not the U.S. Diversifying your portfolio beyond your home shores can help your portfolio better weather tough economic times in the U.S. Similarly, for those concerned about the state of the U.S. dollar, Aflac's business in Japan is conducted in yen; so when the dollar is stumbling, earnings in Japan end up looking even better.
Of course, the Japanese exposure isn't all good news. Mr. Market may be more concerned about the U.S. economy than Japan's, but Japan isn't exactly the shining light of global economic growth. The country has also had an interesting political scene as it seems to go through a new prime minister every fortnight or so.
It seems like there are few guarantees except change when it comes to the future of health care and health-care finance. In the U.S., whether you're Aflac or a traditional insurer like UnitedHealth or WellPoint, the concerns over unsustainably high health-care spending are almost certainly going to bring big changes in the years ahead. In Japan, the country's aging population and fiscal position could also bring changes to the way health care is paid for.
While these changes could mean challenges, it could also mean new opportunities, particularly for a company like Aflac. As a provider primarily of supplemental coverage, many of Aflac's plans pay a fixed amount to the insured, as opposed to requiring the company to pay for some specific medical procedure that could rapidly increase in price. This is a positive for Aflac, but it is also a positive for customers looking to a way to make ends meet when the government or a private insurer isn't shelling out enough to cover the full cost of a health-care issue.
Of course, we do also have to keep in mind that we're talking about two developed-world countries with economies stuck in the mud. Until the economic picture begins to brighten, it could be more of a struggle for Aflac sales agents to convince consumers that they need to shell out for an insurance policy outside of the standard fare.
Is there value?
The short answer is "yes."
If we stack Aflac up against other insurers, we find that its forward price-to-earnings ratio of 5.7 is a steep discount to the multiples of 11 and 8.9 that we find, respectively, with UnitedHealth and WellPoint. Fellow health insurers Aetna (NYS: AET) and Humana (NYS: HUM) carry similar multiples that are well above Aflac's.
Aflac's valuation appears more in line with the big life insurers, but even there it appears to be selling at a discount. MetLife (NYS: MET) has a current forward P/E of 6.2, while Prudential Financial's (NYS: PRU) is 7.
But perhaps we don't even need to go to the trouble of comparing Aflac with these other companies -- as I pointed out yesterday, the company's one-year and normalized 10-year multiples look attractive on an absolute basis. The 11% annual growth Wall Street analysts are expecting may be a bit optimistic, but with the market giving the company so little credit, stellar growth isn't necessary for attractive returns here.
Should you quack along?
The purpose of all of this research hasn't been just because I love reading SEC filings (though I do). Rather, I'm trying to decide which of these companies I should put at the top of my buy list to add to my personal portfolio. Aflac has made a strong case here, but it's competing against a tough group of attractive companies. To stay tuned for my final decision, you can keep an eye on my Motley Fool article feed.
In the meantime, though, hopefully I've given you a lot to think about here. As you digest this and dig into the numbers yourself, you should go ahead and add Aflac to your watchlist to keep up with what's going on at the company. Don't have a watchlist? You're in luck -- you can start one for free by clicking here.
At the time this article was published Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or Facebook. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.